Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials

Human Psychopharmacology

Volumn 20, Issue 5, 2005, Pages 327-341

  Hudson, James I ^a,c   Wohlreich, Madelaine M ^b   Kajdasz, Daniel K ^b   Mallinckrodt, Craig H ^b   Watkin, John G ^b   Martynov, Oleg V ^b  

^a MCLEAN HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Duloxetine; Major depressive disorder; Safety; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; DULOXETINE; IBUPROFEN; MULTIVITAMIN; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; BODY WEIGHT DISORDER; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONSTIPATION; DATA ANALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELECTROCARDIOGRAPHY; EPISTAXIS; ERECTILE DYSFUNCTION; EUROPEAN UNION; FATIGUE; FEMALE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATURIA; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; META ANALYSIS; MYOCLONUS; NAUSEA AND VOMITING; NIGHTMARE; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SWEAT GLAND DISEASE; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UNITED STATES; URINE RETENTION; VAGINA BLEEDING; VISUAL IMPAIRMENT; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BODY WEIGHT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SEXUAL BEHAVIOR; THIOPHENES;

EID: 23244441627     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.696     Document Type: Review

References (46)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
2. Anderson IM. 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19-36.
3. Anderson IM, Tomenson BM. 1995. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 310: 1433-1438.
4. Baldwin DS. 2001. Unmet needs in the pharmacological management of depression. Hum Psychopharmacol 16: S93-S99.
5. Barbey JT, Roose SP. 1998. SSRI safety in overdose. J Clin Psychiatry 59(Suppl. 15): 42-48.
6. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880.
7. Committee for Proprietary Medicinal Products. 1997. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. European Agency for the Evaluation of Medicinal Products: London, UK.
8. Detke MJ, Lu Y, Goldstein DJ, et al. 2002a. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315. Detke MJ, Lu Y, Goldstein DJ, et al. 2002a. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315.
9. Detke MJ, Lu Y, Goldstein DJ, et al. 2002b. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36: 383-390.
10. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. 2004. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and paroxetine-controlled trial. Eur Neuropsychopharmacol 14: 457-470.
11. Edwards JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507-533.
12. Ferguson JM. 2001. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3: 22-27.
13. Garland EJ, Remick RA, Zis AP. 1988. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 8: 323-330.
14. Goldman LS, Alexander RC, Luchins DJ. 1986. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry 47: 225-229.
15. Goldstein DJ, Lu Y, Detke MJ, et al. 2004. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24: 389-399.
16. Goldstein DJ, Mallinckrodt C, Lu Y, et al. 2002. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63: 225-231.
17. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. National Institutes of Mental Health: Rockville, MD.
18. Haddad PM. 2001. Antidepressant discontinuation syndromes. Drug Saf 24: 183-197.
19. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Harvey BH, McEwen BS, Stein DJ. 2003. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry 54: 1105-1117.
21. Hirschfeld RM. 2000. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403: 35-38.
22. Hotopf M, Hardy R, Lewis G. 1997. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170: 120-127.
23. Judge R, Parry MG, Quail D, et al. 2002. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 17: 217-225.
24. Kennedy SH, Dickens SE, Eisfeld BS, et al. 1999. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 56: 201-208.
25. Kessler RC, Berglund P, Demler O, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
26. Lee KC, Finley PR, Alldredge BK. 2003. Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf 2: 233-247.
27. Mackay FR, Dunn NR, Martin RM, et al. 1999. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 49: 892-896.
28. Masand PS. 2003. Tolerability and adherence issues in antidepressant therapy. Clin Ther 25: 2289-2304.
29. McGahuey CA, Gelenberg AJ, Laukes CA, et al. 2000. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26: 25-40.
30. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. 1997. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176-194.
31. Montgomery SA, Henry J, McDonald G, et al. 1994. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53.
32. Nelson JC. 1997. Safety and tolerability of the new antidepressants. J Clin Psychiatry 58(Suppl. 6): 26-31.
33. Olfson M, Marcus SC, Druss B, et al. 2002. National trends in the outpatient treatment of depression. JAMA 287: 203-209.
34. Olver JS, Burrows GD, Norman TR. 2001. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 15: 941-954.
35. Peet M. 1994. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164: 549-550.
36. Peretti S, Judge R, Hindmarch I. 2000. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403: 17-25.
37. Pisani F, Oteri G, Costa C, et al. 2002. Effects of psychotropic drugs on seizure threshold. Drug Saf 25: 91-110.
38. Raskin J, Goldstein DJ, Mallinckrodt C, et al. 2003. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 64: 1237-1244.
39. Sher L. 2002. Prevention of the serotonin reuptake inhibitor discontinuation syndrome. Med Hypotheses 59: 92-94.
40. Song F, Freemantle N, Sheldon TA, et al. 1993. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 306: 683-687.
41. Stafford RS, MacDonald EA, Finkelstein SN. 2001. National Patterns of Medication Treatment for Depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 3: 232-235.
42. Thase ME. 1998. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59: 502-508.
43. Tran PV, Lu Y, Martynov O, Detke MJ. 2003. Safety and tolerability of duloxetine versus paroxetine. Presented at the 156th Annual Meeting of the American Psychiatric Association; San Francisco, CA; May 17-22 2003.
44. Trindade E, Menon D, Topfer LA, et al. 1998. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159: 1245-1252.
45. Witchel HJ, Hancox JC, Nutt DJ. 2003. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23: 58-77.
46. Wong DT, Bymaster FP. 2002. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58: 169-222. uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58: 169-222.